Certara, Inc. (NASDAQ:CERT) Shares Sold by Select Equity Group L.P.

Select Equity Group L.P. lowered its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 11.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 172,488 shares of the company's stock after selling 22,755 shares during the period. Select Equity Group L.P. owned 0.11% of Certara worth $1,837,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Certara by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company's stock worth $132,455,000 after purchasing an additional 38,068 shares during the period. ArrowMark Colorado Holdings LLC increased its holdings in shares of Certara by 164.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after purchasing an additional 3,861,674 shares during the last quarter. Teacher Retirement System of Texas increased its stake in Certara by 13.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company's stock worth $48,542,000 after acquiring an additional 557,348 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Certara by 4.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company's stock valued at $43,494,000 after acquiring an additional 182,042 shares during the period. Finally, Brown Brothers Harriman & Co. grew its stake in shares of Certara by 63.8% during the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock valued at $40,668,000 after buying an additional 1,487,998 shares during the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on CERT shares. Stephens restated an "overweight" rating and set a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price for the company. JMP Securities reiterated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Robert W. Baird lifted their price objective on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Finally, KeyCorp raised their target price on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Stock Performance

NASDAQ CERT traded down $0.09 during trading hours on Tuesday, hitting $11.69. 1,379,364 shares of the stock were exchanged, compared to its average volume of 1,314,796. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -58.45, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $17.76. The stock has a 50-day moving average of $11.76 and a 200 day moving average of $11.75. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. During the same period in the prior year, the company earned $0.10 EPS. The firm's revenue was up 9.7% on a year-over-year basis. As a group, equities research analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.